RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
Trial details
- Registry ID
- NCT06328777
- Phase
- Phase 2, Phase 3
Drug identity checked against registry records
Also recorded as Rese-cel; Resecabtagene autoleucel
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic SclerosisNCT06328777 | Cabaletta Bio | Phase 2, Phase 3 | Recruiting | 2029-07Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |